PND2 AN EPIDEMOLOGIC EVALUATION OF COMORBID CONDITIONS IN PATIENTS WITH MULTIPLE SCLEROSIS  by Livingston, T.P. et al.
moderate and high anticholinergic activity respectively. Frequency of the use of
drugs having anticholinergic activity prescribed along with cholinesterase inhibi-
tors and NMDA receptor antagonist was compared using the Chi square test.
RESULTS: Of the patients with AD, 654 patients were given cholinesterase inhibi-
tors and NMDA receptor antagonist. Most of the AD patients were prescribed with
cholinesterase inhibitors (86.69%) as compared to NMDA receptor antagonist
(14.83%). 98.94% of patients on cholinesterase inhibitors and 93.82% on NMDA
receptor antagonist were co-prescribed drugswith anticholinergic properties. Sim-
ilar percent of patients on cholinesterase inhibitors andNMDA receptor antagonist
were co-prescribed drugswithmild (65.43%vs 63.92%, p0.7723),moderate (22.40%
vs 21.65%, p0.8699) and high (11.11% vs 8.25%, p0.3990) anticholinergic activity.
No statistical difference in prescribing moderate to high anticholinergic agents for
treating Depression, Convulsions and Parkinson’s disease was found in AD pa-
tients being treated with cholinesterase inhibitors and NMDA receptor antagonist.
CONCLUSIONS: Patients with AD receiving cholinesterase inhibitors or NMDA re-
ceptor antagonist appear to be co-prescribed drugs havingmoderate and high level
of anticholinergic activity without any distinction. Physicians should be more pru-
dent in co-prescribing drugs with anticholinergic activity in patients with AD due
to the high risk of adverse reactions.
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OBJECTIVES: To study the prevalence of comorbid conditions in a population of
patients with Multiple Sclerosis (MS).METHODS: In a retrospective analysis, inte-
grated medical and pharmacy claims data (IMS LifeLink™ Health Plan Claims and
Longitudinal Prescriptions databases) were analyzed to select patients with an active
diagnosis of MS (ICD-9 code 340.*) during the 2009 calendar year. The presence of
comorbidities was also determined using ICD-9 codes present on medical claims.
Prescription drug use was evaluated by pharmacy claims and drug-specific billing
codes.RESULTS: From the database, 18,013 patientswithMSwere identified. About
two-thirds (67.6%) of patients were between 18 and 55 years of age, and 77.6%were
female. Evidence of specific chronic conditions was substantial and included: hy-
perlipidemia (seen in 36.1% of patients), HTN (32.9%), diabetes (10.8%), asthma
(8.3%), cardiac arrhythmias (7.2%), COPD (4.5%), and CHF (1.6%). The presence of
any respiratory conditions (asthma or COPD) was present in 11.4% of patients,
cardiovascular conditions (HTN, CHF, arrhythmias) in 37.3%, and metabolic condi-
tions (DM, HTN, hyperlipidemia) in 50.5%. Though the prevalence of many condi-
tions was age and gender dependent, their prevalence was independent of treat-
ments including disease-modifying treatments (DMTs) such as interferon,
glatiramer acetate, and natalizumab. CONCLUSIONS: This analysis illustrates the
complexity of the case-mix of patients with MS. An increasing amount of evidence
suggests that physical and mental comorbidities, and adverse health factors are
common and can affect the disease. Because of the high prevalence of comorbidi-
ties, any treatment decisions should be carefully considered and should be indi-
vidualized in order to optimize outcomes and reduce the potential interactions
between treatment and comorbidities.
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OBJECTIVES:Comorbidities in individualswithMSadd to the complexity of disease
management. A better understanding of the nature and prevalence of comorbid
illness in MSmay improve patient outcomes. The objective of this research was to
gain a better understanding of the comorbid illnesses present in individuals with
MS compared to individualswithoutMS.METHODS:TheNational Health andWell-
ness Survey (NHWS) is an Internet-based annual study of the healthcare attitudes
and behaviors of a US representative adult sample. Demographics and comorbidi-
ties were compared between individuals with diagnosed MS and individuals with-
out MS. RESULTS: Compared to subjects without MS, a greater proportion of sub-
jects with MS reported being female (64.3% vs. 51.3%; p0.001) and being white
(non-hispanic) (78.7% vs. 74.0%; p0.006). Subjects with MS reported more comor-
bidity compared to subjects without MS (Charlson Comorbidity Index: 0.97 vs. 0.82;
p0.001). Neurologic symptoms and conditions (pain 56.7% vs. 37.8%, headache
55.8% vs. 44.6%,migraine 29.5% vs. 16.4%, restless leg syndrome 18.7% vs. 7.8%, and
stroke 5.2% vs. 1.4%; p0.001), and psychiatric symptoms and conditions (sleep
difficulties 43.3% vs. 29.6%, depression 39.7% vs. 23.5%, anxiety 33.0% vs. 22.6%,
insomnia 28.5% vs. 17.8%, and panic disorder 8.2% vs. 3.6%; p0.001) were more
common in subjects with MS compared to those without MS. Rates for hyperten-
sion (33.6% vs. 32.8%; p0.968) and high cholesterol (32.3% vs. 30.9%; p0.669) were
similar but cardiovascular conditions such as angina (4.8% vs. 2.9%; p0.001), ar-
rhythmia (4.8% vs. 2.7%; p0.003), and peripheral arterial disease (3.7% vs. 1.4%;
p0.001) were higher for MS subjects. CONCLUSIONS: As expected, individuals
with MS have significant comorbid illness compared to individuals without MS.
Neurologic and psychiatric conditions and symptoms are common and typically
more prevalent inMS. Cardiovascular risk factors are similar to individualswithout
MS but higher rates of cardiovascular conditions were observed.
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OBJECTIVES: To understand how shift work disorder (SWD) affected the lives of
shift workers (SWs) and how SWD was diagnosed from the perspective of health
care professionals (HCPs) and SWs.METHODS: Two separate online surveys were
administered to: (1) SWs with/out SWD and (2) HCPs. Participation in the SWs
survey required 21 hours per week working shifts in the previous 2 weeks, a
diagnosis of SWD or10 score on the Epworth Sleepiness Scale (ESS), and5 score
on any of the subscales of the Sheehan Disability Scale (SDS). Participation in the
HCP survey required3 years in pre-designated specialties and at least 75% of their
time spent in patient care. RESULTS: A total of 260 respondents complete the SWs
survey and 673 the HCP survey. SWnegatively impacted respondents’ energy level,
social life, and emotional and physical health. SWs also reported a loss of concen-
tration (87%), mistakes (69%), and an injury (11%) at work. Many respondents used
caffeine and 57% of diagnosed respondents received prescription medication to
treat SWD symptoms. Of those SWs without diagnosed SWD, 23% denied having
excessive sleepiness despite scoring10 on the ESS and having functional impair-
ment (SDS). For those SWs who consulted with their HCPs, SWs initiated this con-
versation more than HCPs (82% vs. 13%). HCPs believe that 67% of total SWD is
never suspected by physicians and that 50% of SWD is undiagnosed because SWD
is oftenmasked by other conditions and/ormisdiagnosed.CONCLUSIONS:Respon-
dents reported that excessive sleepiness and insomnia associated with SW seri-
ously impacted their lives at home and at work. SWs do not always recognize their
SWD symptoms and are more likely to initiate a discussion of those symptoms
than HCPs. HCPs believe that SWD is often missed as it is masked by other comor-
bidities or misdiagnosed.
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OBJECTIVES: To assess Parkinson’s Disease (PD) progression using the Hoehn and
Yahr (H&Y) scale over the complete disease course based on systematic literature
reviewwithmeta-analysis. No systematic review of PD studies usingH&Yhas been
undertaken. Such findings could support models to evaluate economic effects of
disease modifying therapies. METHODS: A systematic literature review (PubMed)
was conducted to identify research since 1990 that reported longitudinal H&Y out-
comes to obtain progression time data. Reference lists from retrieved articles were
also reviewed and supplemented with recommendations from an expert neurolo-
gist. Statistical moments (e.g., survival at time t, median time to progress) were
extracted and expected time to progress to the subsequent stage was calculated
assuming a constant hazard rate of progression with a binomial distribution for
progression rates. Average time to progress through all stages of disease was cal-
culated. Random effects meta-analysis was performed to assess heterogeneity be-
tween studies between each stage in progression. RESULTS: Of 554 identified rel-
evant titles, 56 articles were reviewed. Ten studies, including one open label
extension (OLE) trial and nine cohort studies, reported longitudinal H&Y outcomes
for 3,687 patients observed over an average of 13.5 years.Weighted by study sample
sizes, expected time to progress from H&Y 1 to H&Y 5 was 162.1 months. The OLE
trial had longest expected total progression time (431.8 months, N110); other
studies ranged from 102.0 to 171.7 months. Time from H&Y stage 1–stage 2, 2–3,
3–4, and 4–5 were 32.3, 60.5, 42.9 and 26.4 months, respectively. Meta-analysis
indicated significant heterogeneity in progression time between studies (I295%).
Omitting single studies did not affect pooled estimates. CONCLUSIONS: Economic
assessment of impacts of PD disease modification can consider expected progres-
sion rates over the full course of the disease. Progression rates are most rapid from
H&Y stage 4 to 5.
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OBJECTIVES: Relapse reduction is important for multiple sclerosis (MS) because
relapses lead to faster deterioration of patient health status. This study aims to
evaluate the impact of specialty care programs which mainly focus on mail-order,
professional monitoring and assessment for MS patients nationwide, compared to
usual care. METHODS: Administrative claims for people with MS were extracted
from the databases from a pharmacy management company for this retrospective
cohort study. Enrollees with continuous pharmacy benefit eligibility were followed
for three years. Patients exposed to specialty care programs were classified as
specialty care group. Relapses were considered to have occurred when patients
used steroids or were hospitalized due to MS. The outcomemeasures included the
risk, number of relapses, and time to relapse. Logistic, negative binomial, and
Cox-proportional hazards regressions were performed to compare between
groups. RESULTS: Study cohort consisted of 1731 eligible MS patients, of which
1427 received the specialty care. During the study period, 1634 relapses were iden-
tified with amean annual relapse rate of 0.3 among specialty care group versus 0.4
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